The system is specifically designed for the clinical needs of theranostic imaging. Its detectors and collimators are developed for Targeted Radionuclide Therapies carried out with radioisotopes ...
Precision diagnostics in prostate cancer treatment (PREDICT): A phase 2 multi-arm biomarker-based study (Alliance A032102). This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers ...
Radioligand therapy (RLT) with actinium-225 targeting prostate-specific membrane antigen (225 Ac-PSMA) had a "substantial antitumor effect" in heavily pretreated metastatic castration-resistant ...
Reston, VA—A novel prostate cancer treatment— 225 Ac-PSMA-617 radioligand therapy—has been shown to increase the progression free survival (PFS) and overall survival (OS) of metastatic ...
Actinium Pharmaceuticals Inc. has unveiled ATNM-400, a novel non-PSMA-targeting, first-in-class radiotherapy for prostate cancer utilizing the Actinium-225 (Ac-225) radioisotope.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results